Evidence map›Paper›PMID 36467802›Full record

ArticleEJHaem2022

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.

Arleigh McCurdy, Martha Louzada, Christopher P Venner, Alissa Visram, Esther Masih-Khan, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Richard LeBlanc, Michael Sebag, Kevin Song and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 1 country.

Arleigh McCurdyThe Ottawa Hospital Ottawa Ontario Canada.
Martha LouzadaLondon Regional Cancer Center London Ontario Canada.
Christopher P VennerCross Cancer Institute University of Alberta Edmonton Alberta Canada.
Alissa VisramThe Ottawa Hospital Ottawa Ontario Canada.
Esther Masih-KhanPrincess Margaret Cancer Centre Toronto Ontario Canada.ORCID https://orcid.org/0000-0002-7271-0680
Moustafa KardjadjCanadian Myeloma Research Group Vaughan Ontario Canada.
Victor H Jimenez-ZepedaArnie Charbonneau Cancer Institute University of Calgary Calgary Alberta Canada.
Richard LeBlancMaisonneuve-Rosemont Hospital Research Centre University of Montreal Montreal Quebec Canada.
Michael SebagMcGill University Montreal Quebec Canada.
Kevin SongBC Cancer Agency Vancouver General Hospital Vancouver British Columbia Canada.
Darrell WhiteQueen Elizabeth II Health Sciences Centre Dalhousie University Halifax Nova Scotia Canada.
Hira MianJuravinski Cancer Center Hamilton Ontario Canada.ORCID https://orcid.org/0000-0003-1584-1067
Julie StakiwSaskatoon Cancer Centre University of Saskatchewan Saskatoon Saskatchewan Canada.
Anthony ReimanSaint John Regional Hospital Saint John New Brunswick Canada.ORCID https://orcid.org/0000-0002-2706-8764
Muhammad AslamAllan Blair Cancer Centre Regina Saskatchewan Canada.
Rami KotbCancer Care Manitoba Winnipeg Manitoba Canada.
Engin GulCanadian Myeloma Research Group Vaughan Ontario Canada.
Donna ReecePrincess Margaret Cancer Centre Toronto Ontario Canada.
Canadian Apheresis Group · CAOttawa Hospital · CAPrincess Margaret Cancer Centre · CABC Cancer Agency · CACancerCare Manitoba · CADalhousie University · CAHôpital Maisonneuve-Rosemont · CAJuravinski Cancer Centre · CAMcGill University · CAOttawa Regional Cancer Foundation · CASaint John Regional Hospital · CASaskatchewan Cancer Agency · CAUniversity of Alberta · CAUniversity of Calgary · CAUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a real-world setting in Canada between years 2007 and 2020. A total of 445 patients were included in this study: the doublet (Kd/p,

Indexed as

carfilzomibmultiple myelomareal‐world data

Identifiers

PMID36467802
PMCPMC9713064
OpenAlexW4293915832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.